$REPL News

'Replimune Gets Third Try at FDA Approval After Makary Departure' - Wall Street Journal

Replimune: Perhaps The FDA Shakeup Will Get A Mulligan For RP1

Live On CNBC, FDA's Makary Defends Agency's Decision On Replimune's Cancer Drug; Says Three Indepndent Teams Arrived At The Same Conclusions

FDA Rejection Sparks Questions On Replimune Drug Approval Path

Cantor Fitzgerald Downgrades Replimune Group to Neutral

Leerink Partners Downgrades Replimune Group to Market Perform, Lowers Price Target to $2

JP Morgan Downgrades Replimune Group to Underweight

Wedbush Downgrades Replimune Group to Neutral, Lowers Price Target to $2

Jefferies Downgrades Replimune Group to Hold, Lowers Price Target to $2

Replimune Group shares are trading lower after HC Wainwright downgraded the stock from Buy to Sell.

Replimune Group shares are trading lower after HC Wainwright downgraded the stock from Buy to Sell.

HC Wainwright & Co. Downgrades Replimune Group to Sell

Trading Halt: Halt status updated at 5:20:00 PM ET: Quotation Resumption: News and Resumption Times

Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives

Replimune Group shares are trading lower after the US Food and Drug Administration issued a complete response letter, highlighting insufficient evidence for the company's vusolimogene oderparepvec drug to treat advanced cutaneous melanoma.

FDA Issues Complete Response Letter Saying Data Insufficient To Confirm Effectiveness Of Replimune's Vusolimogene Oderparepvec

What's Going On With Replimune Stock Friday?

Trading Halt: Halt status updated at 11:02:26 AM ET: Trading Halt: Halt News Pending

FDA Review Looms As Replimune Faces Weak Technical Setup

Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study